These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial. Phillips G; Guo S; Bender R; Havrdová E; Proskorovsky I; Vollmer T Mult Scler Relat Disord; 2016 Mar; 6():66-72. PubMed ID: 27063626 [TBL] [Abstract][Full Text] [Related]
9. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW; Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990 [TBL] [Abstract][Full Text] [Related]
10. Daclizumab for relapsing remitting multiple sclerosis. Liu J; Wang LN; Zhan S; Xia Y Cochrane Database Syst Rev; 2013 Dec; (12):CD008127. PubMed ID: 24363032 [TBL] [Abstract][Full Text] [Related]
11. No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study. Kappos L; Havrdova E; Giovannoni G; Khatri BO; Gauthier SA; Greenberg SJ; You X; Wang P; Giannattasio G Mult Scler; 2017 Nov; 23(13):1736-1747. PubMed ID: 28080250 [TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials. Diao L; Hang Y; Othman AA; Nestorov I; Tran JQ Clin Pharmacokinet; 2016 Aug; 55(8):943-55. PubMed ID: 26873229 [TBL] [Abstract][Full Text] [Related]
13. Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis. Krueger JG; Kircik L; Hougeir F; Friedman A; You X; Lucas N; Greenberg SJ; Sweetser M; Castro-Borrero W; McCroskery P; Elkins J Adv Ther; 2016 Jul; 33(7):1231-45. PubMed ID: 27251051 [TBL] [Abstract][Full Text] [Related]
14. Daclizumab for relapsing remitting multiple sclerosis. Liu J; Wang L; Zhan SY; Xia Y Cochrane Database Syst Rev; 2012 Apr; (4):CD008127. PubMed ID: 22513956 [TBL] [Abstract][Full Text] [Related]
15. Daclizumab and its use in multiple sclerosis treatment. Milo R; Osherov M Drugs Today (Barc); 2017 Jan; 53(1):7-18. PubMed ID: 28387383 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis. Derfuss T; Bergvall NK; Sfikas N; Tomic DL Curr Med Res Opin; 2015; 31(9):1687-91. PubMed ID: 26121423 [TBL] [Abstract][Full Text] [Related]
17. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Rose JW; Giovannoni G; Wiendl H; Gold R; Havrdová E; Kappos L; Selmaj KW; Zhao J; Riester K; Tsao LC; Greenberg SJ Mult Scler Relat Disord; 2017 Oct; 17():32-40. PubMed ID: 29055471 [TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. Giovannoni G; Kappos L; Gold R; Khatri BO; Selmaj K; Umans K; Greenberg SJ; Sweetser M; Elkins J; McCroskery P Mult Scler Relat Disord; 2016 Sep; 9():36-46. PubMed ID: 27645341 [TBL] [Abstract][Full Text] [Related]
19. Daclizumab for the treatment of adults with relapsing forms of multiple sclerosis. Osherov M; Milo R Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1037-1047. PubMed ID: 28803486 [TBL] [Abstract][Full Text] [Related]
20. Daclizumab for the treatment of relapsing-remitting multiple sclerosis. Herwerth M; Hemmer B Expert Opin Biol Ther; 2017 Jun; 17(6):747-753. PubMed ID: 28286970 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]